Avandia rosiglitazone regulatory update

The U.K.'s MHRA issued a warning about use of GlaxoSmithKline's Avandia rosiglitazone based on evidence that the Type II diabetes drug carries increased cardiovascular risk vs. placebo or Actos piogl...